Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05356117 · ClinicalTrials.gov registry record · NA
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
A NA study of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05356117: Recruiting NA study of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT05356117 is a NA study of Pancreatic Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05356117, a NA study of Pancreatic Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine whether a virtually supervised resistance exercise (RE) intervention combined with protein supplementation (PS) is feasible in pancreatic cancer patients initiating chemotherapy and if it will improve skeletal muscle mass. The names of the study interventions involved in this study are: * Resistance training and protein supplement intake (RE + PS) * Resistance training (RE) * Attention control (AC), home-based stretching
Primary Outcome
The primary outcome is feasibility. Feasibility of the resistance exercise (RE) +protein supplementation (PS) intervention will be defined as the proportion of exercise sessions attended and consumption of the PS. The intervention is considered feasible if the proportion of enrolled participants who complete the exercise sessions and daily PS is ≥70%, respectively.
Conditions Studied
Interventions
- BEHAVIORAL Resistance Training (RT) and Protein Supplementation (PS)
- BEHAVIORAL Resistance Training (RT)
- BEHAVIORAL Attention Control (AC
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2027-08-15 |
| Phase | NA |
What NCT05356117 shows while recruiting
NCT05356117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Resistance Training (RT) and Protein Supplementation (PS) is the first listed.
NCT05356117 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05356117 about?
NCT05356117 is a clinical study titled "Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial". The purpose of this research is to determine whether a virtually supervised resistance exercise (RE) intervention combined with protein supplementation (PS) is feasible in pancreatic cancer patients initiating chemotherapy and if it will improve skeletal muscle mass. The names of the study interven...
What is the current status of trial NCT05356117?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2022-09-01. Estimated completion is 2027-08-15.
What conditions does trial NCT05356117 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05356117?
The interventions under investigation include: Resistance Training (RT) and Protein Supplementation (PS) (BEHAVIORAL), Resistance Training (RT) (BEHAVIORAL), Attention Control (AC (BEHAVIORAL).
Who is sponsoring clinical trial NCT05356117?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05356117 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05356117's enrollment target sits among peer trials
45 162nd of 278 higher than 115 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03588975 · 45 participants · Phase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI